Simpson-Yap, S., Brouwer, E. D., Kalincik, T., Rijke, N., Hillert, J., Walton, C., Edan, G., Spelman, T., Geyes, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A., Ardeshirdavani, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., Bergmann, A., Braune, S., Stahmann, A., Middleton, R., Salter, A., Fox, R., van der Walt, A., Butzkueven, H., Rojas, J., van der Mei, I., Nag, N., Ivanov, R., Olival, G. S. d., Dias, A. E., Magyari, M., Brum, D. G., Mendes, M. F., Alonso, R., Nicholas, R., Bauer, J., Chertcoff, A., Zabalza, A., Arrambide, G., Fidao, A., Comi, G., & Peeters, L. (n.d.). 1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis. International journal of epidemiology, 50, . http://access.bl.uk/ark:/81055/vdc_100139931462.0x000011